Phase 3 trials in relapsed and/or refractory MM: convenience
| Regimen (reference) . | Route of administration . | Dosing schedule . | Hospital/clinic visit . | Administration time . |
|---|---|---|---|---|
| KRd (25) | IV | Cycle 1-12: days 1, 2, 8, 9, 15, and 16 of 28-d cycle. Cycle 13-18: days 1, 2, 15, and 16 of 28-d cycle | 2/wk (3 wk on/1 wk off) | >30 min + pretreatment hydration |
| IRd (28) | PO | Days 1, 8, and 15 of 28-d cycle | Every 4 wk | 0 h |
| Rd + elotuzumab (27) | IV | Days 1, 8, 15, and 22 of 28-d cycle (cycles 1 and 2), then days 1 and 15 (cycle 3+) | 1/wk for 8 wk, then every 2 wk | 5 h; need premedication |
| DRd (29) | IV | Days 1, 8, 15m and 22 of 28-d cycle (cycle 1 and 2), days 1 and 15 (cycle 3-6), then every 4 wk thereafter | 1/wk for 8 wk, every 2 wk for 16 wk, then every 4 wk | 6.5 h for the first infusion and 3.5 h for subsequent infusions; need premedication |
| Vd + panobinostat (34) | PO (+ bortezomib IV) | Panobinostat: days 1, 3, 4, 8, 10, and 12 of 21-d cycle; bortezomib: days 1, 4, 8, and 11 | 2/wk (2 wk on/1 wk off) | ∼1 h for bortezomib |
| DVd (33) | IV (+ bortezomib SC) | Daratumumab: days 1, 8, and 15 of 21-d cycle (cycle 1-3), every 3 wk (cycle 4-8), then every 4 wk; bortezomib: days 1, 4, 8, and 11 | 4-5 visits by 21-d cycle | 6.5 h for the first infusion and 3.5 h for subsequent infusions; need premedication |
| Kd (31) | IV | Carfilzomib: days 1, 2, 8, 9, 15, and 16 of 28-d cycle | 2/wk (3 wk on/1 wk off) | >30 min + pretreatment hydration |
| Regimen (reference) . | Route of administration . | Dosing schedule . | Hospital/clinic visit . | Administration time . |
|---|---|---|---|---|
| KRd (25) | IV | Cycle 1-12: days 1, 2, 8, 9, 15, and 16 of 28-d cycle. Cycle 13-18: days 1, 2, 15, and 16 of 28-d cycle | 2/wk (3 wk on/1 wk off) | >30 min + pretreatment hydration |
| IRd (28) | PO | Days 1, 8, and 15 of 28-d cycle | Every 4 wk | 0 h |
| Rd + elotuzumab (27) | IV | Days 1, 8, 15, and 22 of 28-d cycle (cycles 1 and 2), then days 1 and 15 (cycle 3+) | 1/wk for 8 wk, then every 2 wk | 5 h; need premedication |
| DRd (29) | IV | Days 1, 8, 15m and 22 of 28-d cycle (cycle 1 and 2), days 1 and 15 (cycle 3-6), then every 4 wk thereafter | 1/wk for 8 wk, every 2 wk for 16 wk, then every 4 wk | 6.5 h for the first infusion and 3.5 h for subsequent infusions; need premedication |
| Vd + panobinostat (34) | PO (+ bortezomib IV) | Panobinostat: days 1, 3, 4, 8, 10, and 12 of 21-d cycle; bortezomib: days 1, 4, 8, and 11 | 2/wk (2 wk on/1 wk off) | ∼1 h for bortezomib |
| DVd (33) | IV (+ bortezomib SC) | Daratumumab: days 1, 8, and 15 of 21-d cycle (cycle 1-3), every 3 wk (cycle 4-8), then every 4 wk; bortezomib: days 1, 4, 8, and 11 | 4-5 visits by 21-d cycle | 6.5 h for the first infusion and 3.5 h for subsequent infusions; need premedication |
| Kd (31) | IV | Carfilzomib: days 1, 2, 8, 9, 15, and 16 of 28-d cycle | 2/wk (3 wk on/1 wk off) | >30 min + pretreatment hydration |
PO, per os; SC, subcutaneous.